| Literature DB >> 30404633 |
Mateusz Rubinkiewicz1, Piotr Zarzycki1, Agata Czerwińska1, Michał Wysocki1,2, Natalia Gajewska1, Grzegorz Torbicz1, Andrzej Budzyński1,2, Michał Pędziwiatr3,4.
Abstract
INTRODUCTION: Despite the progress in the treatment of colorectal cancer, there is still no optimal strategy for tumours located adjacent to the anal sphincter. This study aims to evaluate oncological and functional results of surgery for rectal cancer in unfavourable locations in proximity to anal sphincters.Entities:
Keywords: Abdominoperineal resection; Intersphincteric resection; Rectal cancer; Transanal TME
Mesh:
Year: 2018 PMID: 30404633 PMCID: PMC6223085 DOI: 10.1186/s12957-018-1513-4
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Fig. 1Study group design (APR—abdominoperineal resection, IR—intersphincteric resection, TaTME—transanal total mesorectal excision)
Groups’ characteristics
| APR | Intersphincteric | TaTME | ||
|---|---|---|---|---|
| Males/females, | 8/5 (52%/48%) | 12/2 (86%/14%) | 19/6 (76%/24%) | 0.345 |
| Median age, years (IQR) | 60 (55–71) | 63 (50–69) | 65 (59.5–72.5) | 0.462 |
| Median BMI, kg/m2 (IQR) | 24.91 (22.31–27.40) | 24.82 (24.15–28.73) | 24.80 (21.94–26.47) | 0.715 |
| ASA class | ||||
| 3 | 3 (23.08%) | 6 (42.86%) | 4 (16%) | 0.175 |
| 2 | 10 (76.92%) | 8 (57.14%) | 21 (84%) | |
| T | ||||
| 3 | 7 (53.85%) | 6 (42.86%) | 15 (60%) | 0.311 |
| 2 | 4 (30.77%) | 4 (28.57%) | 1 (4%) | |
| 1 | 1 (7.69%) | 1 (7.14%) | 2 (8%) | |
| 0 | 1 (7.69%) | 3 (21.43%) | 7 (28%) | |
| N | ||||
| 2 | 0 | 1 (7.14%) | 5 (20%) | 0.381 |
| 1 | 2 (15.38%) | 3 (21.43%) | 5 (20% | |
| 0 | 11 (84.62%) | 10 (71.43%) | 15 (60%) | |
| M | ||||
| 1 | 0 | 0 | 3 (12%) | 0.179 |
| 0 | 13 (100%) | 14 (100%) | 22 (88%) | |
| AJCC | ||||
| 4 | 0 | 0 | 4 (16%) | 0.414 |
| 3 | 4 (30.77%) | 6 (42.86%) | 6 (24%) | |
| 2 | 7 (53.85%) | 5 (35.71%) | 7 (28%) | |
| 1 | 1 (7.69%) | 1 (7.14%) | 4 (16%) | |
| 0 | 1 (7.69%) | 2 (14.29%) | 4 (16%) | |
| Neoadjuvant treatment, | 11 (84.62%) | 13 (92.86%) | 24 (96%) | 0.456 |
| Adjuvant treatment, | 6 (46%) | 7 (50%) | 13(52%) | 0.943 |
| Tumour regression grade (TRG) | ||||
| 3 | 1 (7.69%) | 2 (14.29%) | 3 (12%) | 0.949 |
| 2 | 7 (53.85%) | 7 (50%) | 14 (56%) | |
| 1 | 4 (30.77%) | 3 (21.43%) | 4 (16%) | |
| 0 | 1 (7.69%) | 2 (14.29%) | 4 (16%) | |
AJCC American Joint Committee on Cancer staging system, ASA American Society of Anesthesiologists class, BMI Body Mass Index, IQR interquartile range, T,N,M TNM classification
Primary outcomes
| APR | Intersphincteric | TaTME | ||
|---|---|---|---|---|
| Median operative time, min (IQR) | 240 (210–270) | 212.5 (170–260) | 270 (240–330) | 0.018 |
| Median blood loss, ml (IQR) | 125 (100–200) | 150 (50–200) | 150 (100–200) | 0.856 |
| Intraoperative adverse events (IAE), | 1 (7.69%) | 1 (7.14%) | 1 (4%) | 0.869 |
| Anastomosis | ||||
| Circular stapled | 0 | 1 (7.14%) | 19 (76%) | < 0.001 |
| Hand-sewn coloanal | 0 | 13 (92.86%) | 6 (24%) | |
| No anastomosis | 13 (100%) | 0 | 0 | |
| Sphincter excision (no excision/internal/external) (no. of patients) | 0/0/13 | 1/12/0 | 20/5/0 | < 0.001 |
| Ileostomy, | 0 | 14 (100%) | 25 (100%) | < 0.001 |
| Perioperative morbidity | 4 (30.77%) | 5 (35.71%) | 3 (12%) | 0.181 |
| Perioperative mortality | 0 | 0 | 0 | n/a |
| Clavien-Dindo | ||||
| III | 0 | 2 | 2 | 0.094 |
| II | 4 | 3 | 1 | |
Secondary outcomes
| APR | Intersphincteric | TaTME | ||
|---|---|---|---|---|
| Median CRM, mm (IQR) | 6 (4–7) | 7.5 (2.5–10) | 4 (2.8–8) | 0.682 |
| Median DRM, mm (IQR) | 28 (12–35) | 11 (5–15) | 10 (7–15) | 0.008 |
| Preoperative Wexner | n/a | 2 (1–2) | 0 (0–2) | 0.165 |
| Postoperative Wexner | n/a | 12 (11–14) | 11 (8–12) | 0.475 |
| Preoperative LARS | n/a | 4 (4–6) | 5 (0–12) | 0.999 |
| Postoperative LARS | n/a | 34 (32–34) | 32 (30–37) | 0.397 |